Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.54 |
| ▸ | PHGDH | O43175 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107230 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL87921 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL22216666 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL60131 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL1828721 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL24782761 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL21422636 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL21057384 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL21057351 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL11147768 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106414545-A | Use of a vitrimer-type thermosetting resin composition for manufacturing electrical insulation parts | 阿科玛法国公司 | 2017-02-15 | — | — | CN | claimed |
| EP-2318408-B1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMA (US) | 2016-02-17 | — | — | EP | claimed |
| US-9193722-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-24 | — | — | US | claimed |
| US-9137973-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-22 | — | — | US | claimed |
| EP-2778155-A1 | 2-aminopyridine derivatives useful as kinase inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2014-09-17 | — | — | EP | claimed |
| US-8809335-B2 | Pyrazolopyrimidine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-19 | — | — | US | claimed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | claimed |
| CN-102131807-B | Pyrazolopyridine kinase inhibitors | VERTEX PHARMA | 2013-11-20 | — | — | CN | claimed |
| US-8569337-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-29 | — | — | US | claimed |
| EP-2328896-B1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMA (US) | 2013-10-23 | — | — | EP | claimed |
| US-20050197363-A1 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS (US) | 2005-09-08 | — | — | US | claimed |
| WO-2005068461-A1 | STEREOISOMERIC COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARYX THERAPEUTICS (US) | 2005-07-28 | — | — | WO | claimed |
| US-20020128232-A1 | Heterocyclic angiogenesis inhibitors | STARPHARMA LIMITED (AU) | 2002-09-12 | — | — | US | claimed |
| WO-2002030886-A2 | HETEROCYCLIC ANGIOGENESIS INHIBITORS | MATTHEWS BARRY R (AU) | 2002-04-18 | — | — | WO | claimed |
| US-4820695-A | GRAMNEGATIVE BACTERIA | ELI LILLY AND COMPANY (US) | 1989-04-11 | — | — | US | claimed |
| EP-0124216-B1 | C-20- AND C-23-MODIFIED MACROLIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1988-10-26 | — | — | EP | claimed |
| EP-0103465-B1 | 20-AMINO MACROLIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1986-09-10 | — | — | EP | claimed |
| EP-0124216-A1 | C-20- and C-23-modified macrolide derivatives | ELI LILLY AND COMPANY (US) | 1984-11-07 | — | — | EP | claimed |
| US-4468511-A | C-20- And C-23-Modified macrolide derivatives | ELI LILLY AND COMPANY (US) | 1984-08-28 | — | — | US | claimed |
| EP-0103465-A1 | 20-Amino macrolide derivatives | ELI LILLY AND COMPANY (US) | 1984-03-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | HTR6 3265/4885PHGDH 946/4885MGLL 2413/4885 |
| US-20020128232-A1 | Heterocyclic angiogenesis inhibitors | KDR, CBR3, OGFR | HTR6 2223/4885PHGDH 2341/4885MGLL 3593/4885 |
| US-20050197363-A1 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | CCKBR, GRPR, HRH2 | HTR6 125/4885PHGDH 1061/4885MGLL 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.